3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
20
Breast Neoplasms
11
Prostatic Neoplasms
10
Neoplasms
7
Neoplasm Metastasis
7
Fallopian Tube Neoplasms
7
Pancreatic Neoplasms
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
SCLC,Extensive Stage
1
Recurrence
1
Rectal Neoplasms
1
Prostate Adenocarcinoma
1
Interventions
fludarabine
4
Cyclophosphamide
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Pemetrexed
3
fludarabine phosphate
2
entrectinib
2
durvalumab
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Nivolumab
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
niraparib
×
1 year
×
Clear all
No trials found.